# US 2010/0166737 A1 · P38Alpha as a Therapeutic Target in Bladder Carcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166737 A1
- Document ID: US20100166737A1
- Status: Published application
- Kind: A1
- Application number: 12/597,785
- Filed: 2008-05-16
- Published: 2010-07-01
- Earliest claimed: 2007-05-18
- Assignees: Institut Curie; Centre National De La Recherche Scientifique; Assistance Publique-Hopitaux de Paris; Universite Paris 12
- Inventors: Isabelle Bernard-Pierrot; Francois Radvanyi; Yves Allory
- Web page: https://patentgrep.com/patent/US20100166737A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 13/10: of the bladder
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns methods and compositions for treating bladder carcinoma by p38 inhibitors.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A method for treating a subject suffering of a bladder tumor or carcinoma comprising administering a therapeutically efficient amount of a p38α inhibitor.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the p38α inhibitor is selected from the group consisting of AMG 548, ARQ 101, ARRY-371797, ARRY-614, AR00182263, AZD6703, RPR200765A, RPR203494, BIRB796, SB242235, SB239063, SB681323, R04402257, 803201195, RWJ67657, RWJ67671, RWJ67568, RWJ67411, RWJ66430, KC706, L-167307, SC-80036, SC10-469, SC10-323, SD-282, SCI-496, TAK715, VX-702, VX-850, VX-745, SB202190, SB203580, SB220025, SB239063, SC68376, Compound 37 (Amgen's 657417), SX-011, and SKF-86002.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the p38α inhibitor is a specific p38a inhibitor.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the specific p38α inhibitor is selected from the group consisting of AMG 548, ARRY-371797, ARRY-614, AR00182263, Compound 37 (Amgen's 657417), SX-011, BIRB796, VX-745, SCID-469 and SD-282.

### Claim 18 (depends on 14)

The method according to claim 14, wherein the p38α inhibitor is a siRNA directed against p38α.

### Claim 19 (depends on 14)

The method according to claim 14, wherein the p38α inhibitor is selected from the group consisting of an antisense, an antibody and a ribozyme.

### Claim 20 (depends on 14)

The method according to claim 14, wherein a phosphorylated p38α is detected in a sample from the subject to be treated.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the bladder carcinoma is linked to FGFR3 or RAS mutations.

### Claim 22 (depends on 14)

The method according to claim 14, wherein the subject to be treated has a mutated FGFR3.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the FGFR3 mutation is selected from the group consisting of R248C, S249C, G372C, S373C, Y375C, K652E, K652M, J809G, J809C, J809R, J809L, P250R, G377C, G382R, A393E and N542K.

### Claim 24 (depends on 14)

The method according to claim 14, wherein the p38α inhibitor is administered orally, topically, or parentally.

### Claim 25

A method for selecting a subject suffering of a bladder carcinoma or tumor suitable to be treated by a p38α inhibitor comprising, determining in a sample from a subject if FGFR3 or RAS has a mutation, and selecting the subject for treatment with a p38α inhibitor if said subject has a mutated FGFR3 or RAS.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the FGFR3 mutation is selected from the group consisting of R248C, S249C, G372C, S373C, Y375C, K652E, K652M, J809G, J809C, J809R, J809L, P250R, G377C, G382R, A393E, and N542K.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the FGFR3 mutation is R248C.

### Claim 28 (depends on 26)

The method according to claim 26, wherein the FGFR3 mutation is S249C.

### Claim 29 (depends on 26)

The method according to claim 26, wherein the FGFR3 mutation is G372C.

### Claim 30 (depends on 26)

The method according to claim 26, wherein the FGFR3 mutation is K652E.

### Claim 31 (depends on 26)

The method according to claim 26, wherein the FGFR3 mutation is S249C.

### Claim 32 (depends on 26)

The method according to claim 26, wherein the FGFR3 mutation is Y375C.
